Published in Biosci Rep on August 01, 2012
Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One (2014) 0.91
Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci (2015) 0.89
Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma. Anal Cell Pathol (Amst) (2015) 0.85
MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair. Mol Cell Biol (2013) 0.83
Mechanisms, function and clinical applications of DNp73. Cell Cycle (2013) 0.83
Tumor-suppressor Genes, Cell Cycle Regulatory Checkpoints, and the Skin. N Am J Med Sci (2015) 0.82
Alterations of p63 and p73 in human cancers. Subcell Biochem (2014) 0.81
MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer. Int J Nanomedicine (2014) 0.80
Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor. J Biol Chem (2015) 0.78
Genetically engineered ERα-positive breast cancer mouse models. Endocr Relat Cancer (2014) 0.77
Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Mol Ther (2016) 0.75
Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells. Genet Res Int (2016) 0.75
Enhanced SOX2 expression in retinoblastoma tissues and peripheral blood is associated with the clinicopathological characteristics of the disease. Oncol Lett (2015) 0.75
Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases. Cell Death Dis (2014) 0.75
Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma. BMC Cancer (2017) 0.75
Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells. Oncol Lett (2017) 0.75
Curcumol triggers apoptosis of p53 mutant triple-negative human breast cancer MDA-MB 231 cells via activation of p73 and PUMA. Oncol Lett (2017) 0.75
The retinoblastoma protein and cell cycle control. Cell (1995) 20.21
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
The p53 pathway: positive and negative feedback loops. Oncogene (2005) 9.75
The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev (2003) 8.00
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer (2004) 6.24
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest (1999) 6.13
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (1996) 6.11
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res (1997) 5.92
Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem (2007) 5.49
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 5.33
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Hippo signaling: growth control and beyond. Development (2011) 5.25
Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer (2008) 5.19
CDK inhibitors: cell cycle regulators and beyond. Dev Cell (2008) 5.07
TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol (2008) 5.02
The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol (2001) 4.83
p53: death star. Cell (2000) 4.77
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol (2011) 4.63
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem (2000) 4.49
PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 4.37
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev (1999) 4.13
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (2000) 3.83
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3.68
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer (2007) 3.61
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (1999) 3.55
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev (2001) 3.41
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res (2006) 3.29
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol (2003) 3.12
Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 3.00
Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol (2001) 2.96
p63 and p73: roles in development and tumor formation. Mol Cancer Res (2004) 2.96
BRCA1: mechanisms of inactivation and implications for management of patients. Lancet (2002) 2.85
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest (2007) 2.71
Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol (2004) 2.67
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res (2007) 2.58
The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer (2009) 2.56
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res (2003) 2.51
Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta (2007) 2.45
Dissecting p53-dependent apoptosis. Cell Death Differ (2006) 2.44
Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell (2008) 2.38
AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem (2001) 2.35
Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene (1999) 2.34
Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell (2002) 2.29
Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A (1995) 2.27
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer (2003) 2.26
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res (2011) 2.21
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
Upstream regulation of the hippo size control pathway. Curr Biol (2010) 2.09
RB-dependent S-phase response to DNA damage. Mol Cell Biol (2000) 2.08
Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med (2009) 2.03
Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta (2011) 2.00
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell (1998) 2.00
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res (1998) 1.97
RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (2010) 1.96
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene (2011) 1.95
Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics (2006) 1.94
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer (2010) 1.93
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J (2005) 1.90
DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol (2005) 1.88
Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88
p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene (2011) 1.86
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev (2008) 1.82
Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell (2009) 1.73
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res (2011) 1.66
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med (1996) 1.66
CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res (2010) 1.64
A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci U S A (2004) 1.63
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev (2010) 1.61
Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem (2007) 5.49
Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res (2011) 2.21
The role of varroa mites in infections of Kashmir bee virus (KBV) and deformed wing virus (DWV) in honey bees. Virology (2005) 2.14
LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle (2010) 1.78
MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol (2010) 1.69
Ticks (acari: ixodoidea: argasidae, ixodidae) of China. Exp Appl Acarol (2010) 1.26
Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected]. Proc Natl Acad Sci U S A (2011) 1.17
Biology of Dermacentor silvarum (Acari: Ixodidae) under laboratory conditions. Exp Appl Acarol (2005) 1.16
The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells. Stem Cells (2010) 1.09
miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol (2011) 1.09
Molecular characterization of human homologs of yeast MOB1. Int J Cancer (2010) 1.08
Expansion and evolution of insect GMC oxidoreductases. BMC Evol Biol (2007) 1.05
Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray. Gene (2009) 0.96
LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization. Cell Res (2011) 0.95
Cell surface expression of human ether-a-go-go-related gene (hERG) channels is regulated by caveolin-3 protein via the ubiquitin ligase Nedd4-2. J Biol Chem (2012) 0.92
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis. Mol Cancer Res (2013) 0.92
WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS One (2013) 0.90
BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ. Cell Signal (2013) 0.90
New design tactics in OLEDs using functionalized 2-phenylpyridine-type cyclometalates of iridium(III) and platinum(II). Chem Asian J (2011) 0.87
Highly-dispersed boron-doped graphene nanoribbons with enhanced conductibility and photocatalysis. Chem Commun (Camb) (2014) 0.86
A non-doped phosphorescent organic light-emitting device with above 31% external quantum efficiency. Adv Mater (2014) 0.84
Pax6 directly down-regulates Pcsk1n expression thereby regulating PC1/3 dependent proinsulin processing. PLoS One (2012) 0.82
Retinoic acid inhibits telomerase activity and downregulates expression but does not affect splicing of hTERT: correlation with cell growth rate inhibition in an in vitro cervical carcinogenesis/multidrug-resistance model. Exp Cell Res (2002) 0.82
The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochem Pharmacol (2002) 0.81
An immunoregulatory peptide from salivary glands of the horsefly, Hybomitra atriperoides. Dev Comp Immunol (2008) 0.80
Gene cloning and characterization of novel antinociceptive peptide from the brain of the frog, Odorrana grahami. Biochimie (2011) 0.79
Seasonal abundance and activity of the hard tick Haemaphysalis longicornis (Acari: Ixodidae) in North China. Exp Appl Acarol (2011) 0.78
Cloning and characterization of a male-specific defensin-like antimicrobial peptide from the tick Haemaphysalis longicornis. Dev Comp Immunol (2011) 0.78
tris-Heteroleptic cyclometalated iridium(III) complexes with ambipolar or electron injection/transport features for highly efficient electrophosphorescent devices. Chem Asian J (2014) 0.77
Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol (2013) 0.77
Biosafe nanoscale pharmaceutical adjuvant materials. J Biomed Nanotechnol (2014) 0.76
Novel antimicrobial peptides isolated from the skin secretions of Hainan odorous frog, Odorrana hainanensis. Peptides (2012) 0.76
Antimicrobial peptides from the venoms of Vespa bicolor Fabricius. Peptides (2008) 0.76
Trifunctional Ir(III) ppy-type asymmetric phosphorescent emitters with ambipolar features for highly efficient electroluminescent devices. Chem Commun (Camb) (2014) 0.76
Five novel antimicrobial peptides from the Kuhl's wart frog skin secretions, Limnonectes kuhlii. Mol Biol Rep (2012) 0.75
Underwater Oil Droplet Splitting on a Patterned Template. Langmuir (2017) 0.75
Polychlorinated biphenyls and organochlorine pesticides in surface sediments from the sand flats of Shuangtaizi Estuary, China: levels, distribution, and possible sources. Environ Sci Pollut Res Int (2015) 0.75
A simple and efficient frequency offset estimation algorithm for high-speed coherent optical OFDM systems. Opt Express (2012) 0.75
A robust yellow-emitting metallophosphor with electron-injection/-transporting traits for highly efficient white organic light-emitting diodes. Chemphyschem (2011) 0.75
Regulation of DNA Strand Displacement Using Allosteric DNA Toehold. J Am Chem Soc (2016) 0.75
Bis-Zn(II) salphen complexes bearing pyridyl functionalized ligands for efficient organic light-emitting diodes (OLEDs). Dalton Trans (2017) 0.75
[p300/CBP and Lung Cancer.]. Zhongguo Fei Ai Za Zhi (2009) 0.75
Protein N- and C-termini identification using mass spectrometry and isotopic labeling. Rapid Commun Mass Spectrom (2009) 0.75
[Screening and ammoxidation characteristics of an ammonium oxidizing bacteria group]. Wei Sheng Wu Xue Bao (2015) 0.75
Mechanisms governing phonon scattering by topological defects in graphene nanoribbons. Nanotechnology (2015) 0.75
Novel red phosphorescent polymers bearing both ambipolar and functionalized Ir(III) phosphorescent moieties for highly efficient organic light-emitting diodes. Macromol Rapid Commun (2014) 0.75